Skip to main content
Biotechs going for earlier, better-funded IPOs

Biotech companies are going public earlier and with more initial public offering dollars, which analysts say may reflect more confidence in new technologies, such as gene therapy. Alnylam Pharmaceuticals CEO John Maraganore said this trend reflects the increasing cost of research and development, and an industry that has matured and "proven itself to be a real, sustainable business."

Full Story: